Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
End of content
No more pages to load
From The Source
- DoHAC: National Aboriginal and Torres Strait Islander Suicide Prevention Strategy
- ABS: Provisional Mortality Statistics
- DoHAC: National Women’s Health Advisory Council Annual Report 2023–24
- ACCC proposes not to authorise boycott of private health insurers as part of Catholic hospitals collective bargaining
- Amplar Home Health introduces AI-driven Tissue Analytics solution to transform wound care
- DoHAC: New Aged Care Act: A GPMS guide to digital changes for providers
- DoHAC: Transition periods for manufacturers, importers, and retailers of tobacco products
- ADHA: Keeping prescriptions in one place now makes my health app the first stop for a healthy holiday
- DoHAC: Additional funding to continue work of the National Women’s Health Advisory Council
- DoHAC: Delivering an eating disorder centre for SA
- DoHAC: First Nations Health Governance Group (FNHGG) communique – December 2024
- AMA Submission to draft Fifth National STI Strategy